Menu
A single immune-based technology to improve clinical outcomes against multiple respiratory pathogens
A single immune-based technology to improve clinical outcomes against multiple respiratory pathogens
The global population is constantly facing health threats from known respiratory pathogens such as highly pathogenic influenza (avian influenza, H5N1) and new coronaviruses such as HKU5-CoV-2 and emerging ones such as MERS-CoV and human metapnuemo virus. Host Directed therapeutics such as NanoSTING are being developed to improve medical outcomes for high risk patients, prepare for health emergencies, and minimize the broader impact of seasonal viral outbreaks to the general population.
For millions of years the STING pathway in the cells lining the respiratory tract has detected invading pathogens to launch an immune attack. Disease and death occur when this pathway fails.
For the first time, the STING pathway may be supercharged using a technology called NanoSTING.
When cells sense infection, the intracellular STING pathway is activated by production of intracellular cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
NanoSTING delivers the natural activator of the STING pathway (cGAMP) using lipid nanoparticles independent of the respiratory threat.
Activation of the STING pathway may prevent respiratory infection from occurring and control the extent of disease after exposure has occurred.
NanoSTING particles connect with nasal epithelial cells and the STING agonist (cGAMP) upregulates the interferon in cells that have been infected by a foreign viral pathogen. The interferon helps the body stop replication of the virus and resolve the infection.
With the annual disease burden of seasonal respiratory viruses such as influenza and SARS-CoV-2 and emergence of new threats, the NanoSTING platform addresses today’s pathogens and future challenges.
Problem: Anti-virals, monoclonal antibodies, and vaccines are tailored to the threat and become obsolete as respiratory viruses mutate, become resistant, and sidestep immune responses.
Solution: a acts on our immune system instead of on the respiratory pathogen. It remains effective even as the threat changes over time.
Problem: Anti-virals, monoclonal antibodies, and vaccines must be designed for each pathogen. This requires time to identify the threat, during which individuals suffer and economies and vulnerable.
Solution: NanoSTING-001 is a single solution that is effective independent of the type of respiratory pathogen.
Problem: Vaccines can protect the individual but typically fail to control spread of respiratory viruses between individuals.
Solution: NanoSTING-002 is designed to be combined with current and future vaccines to deliver a comprehensive immune response that protects the recipient from disease and the population by decreasing transmission.
The NanoSTING platform addresses some of the public’s major concerns as individuals and governments handle threats from respiratory viruses.
Rapid Response to outbreaks and new threats
Social isolation: NanoSTING-001 operates in the nose to reduce the amount of respiratory virus and decrease spread from one person to another. There is increased confidence in social gathering as the risk of transmission diminishes.
Masks: NanoSTING-001 actives the immune response in the upper airway to act as an invisible immunological shield. This helps reduce the need and stigma of wearing a physical barrier.
Vaccine Hesitancy: NanoSTING-001 uses natural infection from respiratory pathogens to establish long term protective immunity without the need for vaccines by protecting from serious disease in the short term.
Needle Free Delivery: NanoSTING-002 helps with the development of vaccines that are delivered via the nose instead of using needles.
Supply chain: One manufacturing platform for multiple NanoSTING products
Scalable: Cell-free production at affordable pricing